binance left Huobi Global Coinmarketcap net_left adver left

AstraZeneca says its COVID shot still has role despite global glut

Saturday, April 30, 2022
AstraZeneca says its COVID shot still has role despite global glut © Reuters. FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski

By Natalie Grover and Pushkala Aripaka

(Reuters) -AstraZeneca's COVID-19 vaccine still has a role to play in the fight against the pandemic, even as sales slow and the company charges more in some places, CEO Pascal Soriot said on Friday, the latest drugmaker to warn about a global supply glut.

The comments come after the company reported better-than-expected first-quarter profit and sales driven by the vaccine, its second bestseller last year raking in $3.9 billion. It also confirmed its forecast that 2022 sales of the shot would fall.

The vaccine, branded as Vaxzevria and Covishield, has struggled to compete with rivals made by Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) using mRNA technology, and has hit setbacks with production, rare side-effects and relatively limited shelf life. Approval in the United States has been delayed.

Soriot said the shot, which was seen early in the pandemic as the inoculation of choice for low-income countries, should remain relevant because it's easy to administer and distribute.

Volume will ease, though, because people will probably only need one booster.

"We are no longer in a period of scarcity of vaccine supply - we have oversupply everywhere around the world. So what is out there needs to be used and then of course we'll be able to get a better sense for reordering," he said on a media call.

Rival Johnson & Johnson (NYSE:JNJ) this month pulled its sales forecast for its COVID-19 vaccine, blaming oversupply on hesitancy in developing countries.

So far, 2.9 billion shots of the AstraZeneca (NASDAQ:AZN) vaccine have been delivered globally.

In the first quarter, the company recorded $1.15 billion in sales for the product, the majority of which came from initial contracts, but that number eclipsed analysts' consensus forecast of $739 million, cited by Credit Suisse (SIX:CSGN).

AstraZeneca's shares were down 0.6% in early afternoon trading, underperfoming London's blue-chip index.

The company has started earning a modest profit on the vaccine, which was initially sold at-cost, but it will continue selling in low-income countries on a non-profit basis.

Apart from the vaccine, AstraZeneca also has a COVID-19 treatment, Evusheld, which has been authorised in many regions including the United States, United Kingdom and European Union for preventing infections in people whose immune system is too weak to respond to vaccines.

The drug generated $469 million in first-quarter revenue, below the consensus forecast of $480 million, cited by Credit Suisse.

Access to the drug in the United States has been limited by logistical bottlenecks that are being addressed, Soriot said, adding Britain was one of the few developed countries that has not ordered Evusheld.

"It's a sad situation, quite frankly, because people who are immunocompromised are really suffering from the COVID crisis."

CANCER

AstraZeneca - which unveiled plans to open an R&D centre in Cambridge, Massachusetts designed to serve as the new headquarters for rare disease unit Alexion (NASDAQ:ALXN), which it bought last summer - relies on cancer drugs for about a third of its total product sales.

Even though COVID-19 levels are beginning to wane, access to cancer diagnoses and treatment has still not rebounded to pre-pandemic levels. Things should normalise over the next few months, Soriot predicted.

Meanwhile, the company pared back its expectations for China, which accounted for about 16% of total revenue last year.

The Anglo-Swedish drugmaker said it expected sales there to decline by a mid-single-digit percentage in 2022, largely due to the impact of a programme designed to bring down the prices of off-patent drugs in the country.

"The future for China, we believe is still very strong and we expect to return to growth in the next couple of years," Soriot said, cautioning that lockdowns in China this year could hurt the uptake of cancer and other drugs.

Leave your comment
HOT AUTO TRADE BOT SOFTWARE ig right nyse right Neteller adver right
APPROVED BROKERS
rakuten_main right top net_home_top HOT AUTO TRADE BOT SOFTWARE Binance _ main right top fbs_main right top tifia_main right top
18-05-2022 13:44:12 (UTC+7)

EUR/USD

1.0521

-0.0026 (-0.25%)

Summary

↑ Sell

Moving Avg:

Buy (1)

Sell (11)

Indicators:

Buy (1)

Sell (7)

EUR/USD

1.0521

-0.0026 (-0.25%)

Summary

↑ Sell

Moving Avg:

Buy (1)

Sell (11)

Indicators:

Buy (1)

Sell (7)

GBP/USD

1.2444

-0.0046 (-0.37%)

Summary

↑ Sell

Moving Avg:

Buy (3)

Sell (9)

Indicators:

Buy (0)

Sell (9)

USD/JPY

129.20

-0.19 (-0.15%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (9)

Sell (0)

AUD/USD

0.7018

-0.0011 (-0.16%)

Summary

↑ Sell

Moving Avg:

Buy (1)

Sell (11)

Indicators:

Buy (1)

Sell (7)

USD/CAD

1.2825

+0.0016 (+0.12%)

Summary

↑ Buy

Moving Avg:

Buy (11)

Sell (1)

Indicators:

Buy (7)

Sell (1)

EUR/JPY

135.93

-0.55 (-0.40%)

Summary

Sell

Moving Avg:

Buy (4)

Sell (8)

Indicators:

Buy (1)

Sell (3)

EUR/CHF

1.0474

-0.0003 (-0.02%)

Summary

↑ Buy

Moving Avg:

Buy (9)

Sell (3)

Indicators:

Buy (6)

Sell (0)

Gold Futures

1,809.05

-9.85 (-0.54%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (0)

Sell (8)

Silver Futures

21.559

-0.191 (-0.88%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (1)

Sell (9)

Copper Futures

4.2207

-0.0116 (-0.27%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (0)

Sell (8)

Crude Oil WTI Futures

110.19

+0.56 (+0.51%)

Summary

Neutral

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (4)

Sell (4)

Brent Oil Futures

112.06

+0.13 (+0.12%)

Summary

Neutral

Moving Avg:

Buy (5)

Sell (7)

Indicators:

Buy (4)

Sell (4)

Natural Gas Futures

8.189

-0.125 (-1.50%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (2)

Sell (6)

US Coffee C Futures

228.63

+3.83 (+1.70%)

Summary

Neutral

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (2)

Sell (6)

Euro Stoxx 50

3,741.51

+56.17 (+1.52%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (10)

Sell (0)

S&P 500

4,088.85

+80.84 (+2.02%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (9)

Sell (0)

DAX

14,185.94

+221.56 (+1.59%)

Summary

↑ Buy

Moving Avg:

Buy (11)

Sell (1)

Indicators:

Buy (8)

Sell (0)

FTSE 100

7,518.35

+53.55 (+0.72%)

Summary

↑ Buy

Moving Avg:

Buy (10)

Sell (2)

Indicators:

Buy (6)

Sell (1)

Hang Seng

20,577.00

-25.52 (-0.12%)

Summary

↑ Sell

Moving Avg:

Buy (2)

Sell (10)

Indicators:

Buy (0)

Sell (8)

US Small Cap 2000

1,840.30

+56.87 (+3.19%)

Summary

Neutral

Moving Avg:

Buy (4)

Sell (8)

Indicators:

Buy (5)

Sell (3)

IBEX 35

8,475.70

+122.00 (+1.46%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (11)

Sell (0)

BASF SE NA O.N.

50.690

+1.395 (+2.83%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (8)

Sell (0)

Bayer AG NA

64.12

+0.91 (+1.44%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (7)

Sell (0)

Allianz SE VNA O.N.

202.25

+3.43 (+1.73%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (10)

Sell (0)

Adidas AG

183.30

+3.24 (+1.80%)

Summary

↑ Buy

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (9)

Sell (0)

Deutsche Lufthansa AG

6.827

+0.131 (+1.96%)

Summary

Buy

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (4)

Sell (2)

Siemens AG Class N

116.50

+2.90 (+2.55%)

Summary

↑ Buy

Moving Avg:

Buy (10)

Sell (2)

Indicators:

Buy (9)

Sell (1)

Deutsche Bank AG

9.538

+0.319 (+3.46%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (8)

Sell (0)

 EUR/USD1.0521↑ Sell
 GBP/USD1.2444↑ Sell
 USD/JPY129.20↑ Buy
 AUD/USD0.7018↑ Sell
 USD/CAD1.2825↑ Buy
 EUR/JPY135.93Sell
 EUR/CHF1.0474↑ Buy
 Gold1,809.05↑ Sell
 Silver21.559↑ Sell
 Copper4.2207↑ Sell
 Crude Oil WTI110.19Neutral
 Brent Oil112.06Neutral
 Natural Gas8.189↑ Sell
 US Coffee C228.63Neutral
 Euro Stoxx 503,741.51↑ Buy
 S&P 5004,088.85↑ Buy
 DAX14,185.94↑ Buy
 FTSE 1007,518.35↑ Buy
 Hang Seng20,577.00↑ Sell
 Small Cap 20001,840.30Neutral
 IBEX 358,475.70↑ Buy
 BASF50.690↑ Buy
 Bayer64.12↑ Buy
 Allianz202.25↑ Buy
 Adidas183.30↑ Buy
 Lufthansa6.827Buy
 Siemens AG116.50↑ Buy
 Deutsche Bank AG9.538↑ Buy
Mua/Bán 1 chỉ SJC
# So hôm qua # Chênh TG
SJC Eximbank6,825/ 6,925
(0/ 0) # 1,852
SJC HCM6,825/ 6,925
(0/ 0) # 1,852
SJC Hanoi6,825/ 6,927
(0/ 0) # 1,854
SJC Danang6,825/ 6,927
(0/ 0) # 1,854
SJC Nhatrang6,825/ 6,927
(0/ 0) # 1,854
SJC Cantho6,825/ 6,927
(0/ 0) # 1,854
Cập nhật 18-05-2022 13:44:13
Xem lịch sử giá vàng SJC: nhấn đây!
ↀ Giá vàng thế giới
$1,811.32-3.36-0.19%
Live 24 hour Gold Chart
ʘ Giá bán lẻ xăng dầu
Sản phẩmVùng 1Vùng 2
RON 95-V30.58031.190
RON 95-III29.98030.570
E5 RON 92-II28.95029.520
DO 0.05S26.65027.180
DO 0,001S-V27.45027.990
Dầu hỏa 2-K25.16025.660
ↂ Giá dầu thô thế giới
WTI$112.93+2.42.12%
Brent$112.01+3.062.73%
$ Tỷ giá Vietcombank
Ngoại tệMua vàoBán ra
USD22.955,0023.265,00
EUR23.783,5625.115,95
GBP28.150,0329.351,12
JPY173,94184,14
KRW15,7819,22
Cập nhật lúc 13:36:56 18/05/2022
Xem bảng tỷ giá hối đoái
binance main right Fxpro Main Right aetos main right adver main right